These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 9869561

  • 1. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G, Berry V.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):29-34. PubMed ID: 9869561
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G, Berry V.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):35-40. PubMed ID: 9869562
    [Abstract] [Full Text] [Related]

  • 3. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Berry V, Thorburn CE, Knott SJ, Woodnutt G.
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514
    [Abstract] [Full Text] [Related]

  • 4. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
    Berry V, Hoover J, Singley C, Woodnutt G.
    Antimicrob Agents Chemother; 2005 Mar; 49(3):908-15. PubMed ID: 15728883
    [Abstract] [Full Text] [Related]

  • 5. Elements of design: the knowledge on which we build.
    MacGowan AP.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():6-11. PubMed ID: 14759228
    [Abstract] [Full Text] [Related]

  • 6. Proof of concept: performance testing in models.
    Craig WA.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():12-7. PubMed ID: 14759229
    [Abstract] [Full Text] [Related]

  • 7. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae.
    Garau J.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():28-35. PubMed ID: 14759231
    [Abstract] [Full Text] [Related]

  • 8. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
    Gómez-Lus ML, García Y, Valero E, Amores R, Fuentes F.
    Rev Esp Quimioter; 2000 Sep; 13(3):306-13. PubMed ID: 11086282
    [Abstract] [Full Text] [Related]

  • 9. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.
    MacGowan AP, Noel AR, Rogers CA, Bowker KE.
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2599-603. PubMed ID: 15215115
    [Abstract] [Full Text] [Related]

  • 10. Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.
    Jacobs MR.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():18-27. PubMed ID: 14759230
    [Abstract] [Full Text] [Related]

  • 11. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance.
    Craig WA.
    Am J Med; 2004 Aug 02; 117 Suppl 3A():16S-22S. PubMed ID: 15360093
    [Abstract] [Full Text] [Related]

  • 12. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
    File TM, Jacobs MR, Poole MD, Wynne B, 546, 547, 548, 549, 550, 551, 556, 557 and 592 Clinical Study Groups.
    Int J Antimicrob Agents; 2002 Oct 02; 20(4):235-47. PubMed ID: 12385678
    [Abstract] [Full Text] [Related]

  • 13. Pulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs differ.
    Gracia M, Martínez-Marín C, Huelves L, Giménez MJ, Aguilar L, Carcas A, Ponte C, Soriano F.
    Antimicrob Agents Chemother; 2005 Mar 02; 49(3):996-1001. PubMed ID: 15728894
    [Abstract] [Full Text] [Related]

  • 14. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan 02; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM, Garau J, Jacobs MR, Wynne B, Twynholm M, Berkowitz E.
    Int J Antimicrob Agents; 2005 Feb 02; 25(2):110-9. PubMed ID: 15664480
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B, Sánchez-Alvarez J, García-Mendez E, Sabriá M, Santos J, Pallarés R, Twynholm M, Dal-Ré R, 620 Clinical Study Group.
    J Antimicrob Chemother; 2006 Mar 02; 57(3):536-45. PubMed ID: 16446376
    [Abstract] [Full Text] [Related]

  • 17. A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.
    Bantar C, Nicola F, Fernandez Canigia L, Arenoso HJ, Soutric J, Montoto M, Blanco M, Smayevsky J, Jasovich A.
    J Chemother; 2000 Jun 02; 12(3):223-7. PubMed ID: 10877517
    [Abstract] [Full Text] [Related]

  • 18. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.
    Andes D, Craig WA.
    Antimicrob Agents Chemother; 1998 Sep 02; 42(9):2375-9. PubMed ID: 9736566
    [Abstract] [Full Text] [Related]

  • 19. In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
    Moine P, Vallée E, Azoulay-Dupuis E, Bourget P, Bédos JP, Bauchet J, Pocidalo JJ.
    Antimicrob Agents Chemother; 1994 Sep 02; 38(9):1953-8. PubMed ID: 7811003
    [Abstract] [Full Text] [Related]

  • 20. [Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects].
    Lode H.
    Dtsch Med Wochenschr; 1999 Dec 03; 124(48):1459-61. PubMed ID: 10615328
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.